BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal
BioNTech is branching out into CTLA-4 as part of a deal with the crew behind OncoImmune.
BioNTech and OncoC4 put out word Monday that they had reached an exclusive deal to co-develop and co-commercialize OncoC4’s monoclonal antibody candidate for a variety of cancer indications.
The deal will see BioNTech paying OncoC4, a spinout of OncoImmune, $200 million upfront for ONC-392, OncoC4’s anti-CTLA-4 candidate — plus undisclosed milestone payments and tiered royalties. On top of that, the companies will jointly develop the drug and split development costs in several solid tumor indications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.